Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  BioPharma  /  Heeft CytoDyn het ultieme anti-HIV-middel??

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Heeft CytoDyn het ultieme anti-HIV-middel??

1.071 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 54 »» | Laatste | Omlaag ↓
  3. Fortuno 29 maart 2020 18:49
    quote:

    FatCool schreef op 29 maart 2020 18:18:

    [...]
    Vanaf midden februari in de daling naar beneden. De eerste op $1.22, daarna nog bijgekocht op lagere koersen.

    Ik ben ingestapt voor de bijzonder sterke resultaten met kanker. HIV gaat het geld brengen om de rest te financieren.

    Covid-19 is bijvangst, hoewel heel belangrijk om de paniek (en ellende) de wereld uit te krijgen.

    Hopelijk gaan we wel flink hoger op korte termijn, anders is CytoDyn zo een keer overgenomen. Een echt koersdoel heb ik niet, ligt er gewoon aan hoe het verder gaat.

    Die Amerikanen zijn ongelofelijke pompers :).

    fc
    Pompers zijn het:), maar ook soms super irritante bashers.

    Voor een overname ben ik niet zo bang. De CEO weet wat we waard zijn en heeft meerdere keren aangegeven niets ‘weg te geven’. Hij weet wat de huidige ah’s hebben doorstaan en hoe loyaal die zijn geweest. Ik zeg dit o.b.v. 3-4 jarig aandeelhouderschap.
    Momenteel heeft hij het over een high triple digit waarde.
    Klinkt belachelijk, totdat je de markten in kaart hebt gebracht.

    Zeker goed om hier geen koersdoel te hebben. Zelf denk ik nu in termen van een minimale koers/ waarde en dan denk ik dat die bodemwaarde $5 is (binnen een jaar).
    Het is dat ik al sterk overweight ben in dit aandeel, want ik ken nu geen betere belegging dan dit aandeel.
    Zit nu zelf op een aankoopgemiddelde van $0.46.
    Sinds eerste aankoop nooit iets verkocht alleen maar bijgekocht.
  5. forum rang 6 Tordan 29 maart 2020 18:53
    quote:

    greedfearfear schreef op 29 maart 2020 18:53:

    [...]

    Het schijnt dat ze ook in Frankfurt genoteerd staan.
    Zelf koop ik op de OTC markt in US via Binck.
    Kan denk ik ook via Lynx of Interactive brokers.
    Degiro volgens mij niet.
    Dank je, heb zowel Binck als de Giro. Moet dus lukken. Ga er eens goed naar kijken.
  7. [verwijderd] 30 maart 2020 12:09
    Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

    VANCOUVER, Washington, March 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that an additional three critically ill COVID-19 patients have been treated with leronlimab. These additional patients increase the total to 10 patients receiving leronlimab treatment under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).

    The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week.

    Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, “The preliminary results observed in patients who were severely ill with COVID-19 and treated with leronlimab are encouraging. Although the data set is still small, we saw fairly rapid and positive laboratory responses in all 4 patients treated, and in three of the 4 patients these laboratory results were associated with a favorable clinical outcome. We eagerly await the results of additional patients treated under the FDA’s emergency IND program, as well as the results of several randomized clinical trials about to start.”

    Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, added, “We remain encouraged and hopeful that leronlimab will help patients from this devastating and relentless disease. We will aggressively pursue treatment for COVID-19 patients, and to explore leronlimab’s role in helping to alleviate the impending burden of supply chain and institutional capacity issues.”
  9. [verwijderd] 30 maart 2020 20:45
    Fox news van vandaag:

    New Jersey doctor gives update on use of hydroxychloroquine, remdesivir on coronavirus patients

    www.foxnews.com/media/coronavirus-pat...

    The chief physician executive at Hackensack Meridian Health in New Jersey discussed on “Fox & Friends” how drugs meant to treat other conditions are now being used to help treat COVID-19 patients.

    “Anything that might work, it's nice to get out there,” Dr. Daniel Varga said on Monday. “It's great to use it in emergency situations, use it for compassionate use. Even better to get it out in clinical trials.”

    Varga made the comments responding to a report where two coronavirus patients in New York City were moved out of the intensive care unit after taking an experimental drug typically used to treat HIV and breast cancer. The patients went from being on ventilators in the ICU to a regular hospital in a matter of days, The Daily Mail reported. Studies reportedly suggest the drug, leronlimab, calms the overly aggressive immune response that could lead to pneumonia and even death.

    “I don't know the drug personally, but the studies we're seeing is that, like several drugs we’re trying to use right now in COVID-19, it works predominantly by toning down the immune response that the virus participates in the lung so that the lung doesn't get injured,” Varga said.

    On Monday, Dr. Varga described “three big buckets of clinical innovation” during the coronavirus outbreak.

    He said the first bucket is figuring out how to optimize standard care.

    “One of the things we’re seeing in people who have to get ventilated because of COVID-19 is this use of what’s known as prone ventilation, where you actually lay the patient on their belly while they are ventilated,” Varga said. “What it tends to do is lets the lungs expand more easily so you can get more oxygen down into the lungs and that's been a really big asset in trying to get these folks through their lung injury.”

    “We’re doing clinical trials right now with some antiviral drugs,” Varga said. “The most common one is remdesivir. We’re using that for both moderate and severe patients. We have enrolled patients in both of those trials. Looking at some other antiviral drugs as well.”

    In a press conference earlier this month, President Donald Trump and Food and Drug Administration (FDA) Commissioner Dr. Stephen Hahn described several approaches under testing, including remdesivir, which is being tried in at least five separate experiments, and chloroquine as well as hydroxychloroquine, drugs used to treat malaria.

    Developed by Gilead Sciences, remdesivir is described as an “investigational broad-spectrum antiviral treatment.” Previously, remdesivir was used to treat humans with Ebola.

    When host Brian Kilmeade asked Varga how coronavirus patients are responding to remdesivir, he said: “It’s hard to say.”

    “We’ve had some folks who’ve been on remdesivir who’ve done well and gone home,” Varga explained. “We have folks who are on it right now that are still intubated and in the ICU.”

    Chloroquine and the similar drug, hydroxychloroquine, have shown encouraging signs in small, early tests against the novel coronavirus, but they have yet to be studied during a controlled clinical trial.

    President Trump has spoken out about the importance of trying new treatments in hopes that we can learn where there's room for optimism and where there is not. He has touted the drugs used in malaria cases as a possible response to the coronavirus and now the FDA put in place an emergency use authorization to try these drugs despite clear evidence of their effectiveness.

    “We are using hydroxychloroquine as an off-label use,” Varga said on Monday. “We use it for our intubated patients for the most part. We’re also using it for some of our nursing home patients because that's a group that you don't want to get sick, don't want to it to spread because they're so vulnerable.”

    “And the other trial that we are looking at right now that we hope to get launched later this week, we’ve actually had it fast-tracked up until now, is actually using hydroxychloroquine for what we call chemoprophylaxis or prevention for front-line caregivers,” he added.

    Chemoprophylaxis refers to the administration of a medication to prevent the development of a disease, according to Medicinenet.com.

    Varga went on to say that there are currently 1,400 coronavirus patients in Hackensack Meridian Health facilities, with more than 300 in the ICU and more than 300 on ventilators.

    “We’re probably using the hydroxychloroquine recipe in some way shape or form in about three-quarters of our patients right now,” Varga said.
  10. Fortuno 30 maart 2020 22:34
    quote:

    FatCool schreef op 30 maart 2020 18:03:

    Er was een mooie kans om nog wat aandelen op te vegen rond de $2 een uurtje geleden.

    Maar ik heb er genoeg en ik blijf rustig zitten :).

    fc
    Close $ 2,61. Pas het begin.

    Is zelfs nog rond $ 1,90 geweest door sukkels die nadat $ 3,50 was geraakt een stop loss op $2 hebben geplaatst.
    Dat is vragen om problemen.

    Hoop dat we morgen nadere info krijgen over de CV patienten 5 tm 7.
    Dat er nog eens 3 patienten zijn toegevoegd betekent m.i. dat ook de respons van patienten 5 tm 7 goed moet zijn geweest.
  12. Fortuno 30 maart 2020 22:39
    quote:

    FatCool schreef op 30 maart 2020 22:34:

    Gezien het artikel/Fox News komen we langzaam in zicht. Remdesivir: moeilijk om wat van te zeggen. Hydrochloroquine: tsja, we hebben niets anders...

    Dus Leronlimab is meer dan welkom!!

    fc
    We komen in beeld. Jammer dat er een arts geinterviewd werd die Leronlimab nauwelijks leek te kennen en niet de moeite had genomen om zich er echt in te verdiepen.
  13. [verwijderd] 30 maart 2020 22:40
    quote:

    greedfearfear schreef op 30 maart 2020 22:34:

    Hoop dat we morgen nadere info krijgen over de CV patienten 5 tm 7. Dat er nog eens 3 patienten zijn toegevoegd betekent m.i. dat ook de respons van patienten 5 tm 7 goed moet zijn geweest.
    Ja, ziet er heel hoopvol uit.

    Er zal niet veel aan verdiend worden, maar geweldig goed voor imago/reputatie van CytoDyn.

    Hopelijk komt ook de BLA eerdaags.

    fc
  14. [verwijderd] 30 maart 2020 22:43
    quote:

    greedfearfear schreef op 30 maart 2020 22:39:

    We komen in beeld. Jammer dat er een arts geinterviewd werd die Leronlimab nauwelijks leek te kennen en niet de moeite had genomen om zich er echt in te verdiepen.
    Inderdaad. Maar wat hij zei was niet goed voor de andere medicijnen. Daarmee komt Leronlimab vanzelf bovendrijven.

    Vermoedelijk komt het ziekenhuis waar de testen plaatsvinden eerdaags wel naar buiten. En dan pikt Cuomo of Trump het wel op...

    fc
  15. [verwijderd] 31 maart 2020 08:05
    Dr. Marc Siegel describes HIV drug as 'very exciting' potential coronavirus treatment

    www.foxnews.com/media/dr-marc-siegel-...

    Fox News medical contributor Dr. Marc Siegel told "Tucker Carlson Tonight" Monday that an experimental drug typically used to treat HIV and breast cancer may be a promising treatment for the coronavirus.

    On Friday, the Daily Mail reported that two coronavirus patients in New York City were moved out of the intensive care unit after taking leronlimab, which is said to calm the immune system's overly aggressive response to the virus that could lead to pneumonia or death. The Daily Mail reported that the patients went from being on ventilators in the ICU to a regular hospital in a matter of days.

    "It is actually a very exciting drug that's been used in ten patients around the country," Siegel told host Tucker Carlson. "Because you know what it does? It decreases the inflammation we are seeing when we have a reaction to COVID-19."

    "In other words, people out there should know it's not the virus itself that is causing this pneumonia. It’s an exuberant immune response ... a storm of immune cells. This new drug blocks that, while at the same time revving up your own regular immune response. And it looks very promising at keeping people off of ventilators - or if they're on ventilators, getting them off ventilators by decreasing this inflammation."

    Siegel also noted that N-Acetyl Cysteine (NAC), a drug generally used to fight severe asthma, is also being used in tandem with the blood thinner Heparin, "to decrease this inflammation or exuberant response in the lungs and it too has shown some effect at our goal here, which is getting people off ventilators or preventing them going on ventilators."

    Over the weekend, the Food and Drug Administration instituted an emergency use authorization to treat coronavirus patients with anti-malarial drugs chloroquine and hydroxychloroquine, both of which have been touted by President Trump as potential coronavirus treatments.

    Both drugs have shown encouraging signs in small, early tests against the novel coronavirus, but they have yet to be studied during a controlled clinical trial.

    "It's been shown in the test tube to fight COVID-19 effectively," Siegel said. "The real question is how early in the game to use it. In other words, it may be that it's best used ... as a prevention, as a prophylactic or early when you first start to see symptoms.

    "I think the hydroxychloroquine is more useful earlier on to decrease the amount of virus that is circulating and causing the damage."
  16. [verwijderd] 31 maart 2020 08:08
    Het woord Leronlimab gaat rond...

    Vancouver company has possible treatment for coronavirus

    VANCOUVER, Wash. — Cases are on the rise and health care workers are racing to help those who are testing positive for coronavirus.

    A Vancouver company, CytoDyn, is looking to help with a drug it originally intended for cancer and HIV.

    The drug, Leronlimab, is designed to help immune systems but is not officially in production. In fact, it’s still in the testing phase.

    But now, that drug is also being tested on coronavirus patients.

    The FDA has granted emergency investigational new drug approval, which has allowed a doctor to give patients battling the coronavirus this drug.

    “The coronavirus kills people because of acute respiratory distress in the lungs, because of inflammation in the lungs. Our drugs will take the inflammation down immediately,” said Nader Pourhassan, president and CEO of CytoDyn.

    And now CytoDyn says that drug is helping to save lives.

    “One of the patients became alert and extubated -- they took the tube out -- didn’t need a ventilator anymore. This happened in three days,” Pourhassan said.

    Nader says 10 patients have received the drug. Of them, four have seen benefits to their immune system, and of those four, two were removed from ICU.

    CytoDyn is still awaiting results on the other six.

    It is working toward making more of its drug and getting approval from the FDA to administer it to more people.

    Pourhassan says they have gotten requests from hospitals all over the country and world.

    katu.com/news/coronavirus/vancouver-c...
  18. [verwijderd] 31 maart 2020 12:07
    Terwijl iedereen zit te prutsen met bedrijfjes in testen en vaccines gebeurt hier het echte werk :).

    fc

    FDA Clears CytoDyn’s Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

    VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the U.S. Food and Drug Administration (FDA) just provided clearance for initiation of a Phase 2 trial with CytoDyn’s leronlimab to treat COVID-19 patients with mild to moderate indications. The Company’s investigational new drug, leronlimab, has been administered to 10 severely ill patients with COVID-19 at a leading medical center in the New York City area under an emergency IND recently granted by the FDA. The treatment with leronlimab is intended to serve as a therapy for patients who experience mild-to-moderate respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).

    The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of leronlimab in patients with mild to moderate documented COVID-19 illness and calls for 75 planned patients in up to 10 centers in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.

    Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, “We are very pleased with the FDA’s responsiveness to facilitate the commencement of this important Phase 2 trial. In light of the test results of the various immunologic markers from the critically ill patients treated under the emergency IND, we remain hopeful that leronlimab may be therapeutically beneficial to those COVID-19 patients with mild to moderate indications.”

    Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “The FDA has been very collaborative with our team to accelerate the opportunity to introduce a potentially beneficial treatment to so many patients affected by this horrific pandemic. We hope to complete enrollment of this trial very quickly.”
  19. [verwijderd] 31 maart 2020 12:37
    En nog meer goed nieuws. "Verdunning" op effectief $3.60.

    fc

    CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

    VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it completed a new non-dilutive convertible debt offering with an institutional investor, which provides $15 million of immediately available capital. The note, has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. During the first six months following the issue date, the investor may convert principal into common stock up to 1 million shares per month after which all or any part of the outstanding balance of the note is convertible into common stock.

    Craig S. Eastwood, Chief Financial Officer of CytoDyn, stated, “We are pleased to close on this round of funding as we begin our journey towards commercialization. Non-dilutive capital of this nature gives us the momentum we need to forge ahead with our therapeutic indications and provides a foundation to bring leronlimab to market, which is targeted for the fourth quarter of 2020.”
  20. [verwijderd] 31 maart 2020 23:59
    www.youtube.com/watch?v=cNO0fST7E2o&a...

    De studie voor ernstig zieke patienten is een fase 3 studie. Ongeveer 100 patiënten zou voldoende kunnen zijn.

    De studie voor "mild/moderate" patiënten is een fase 2 studie. Met 75 patiënten, 50 op Leronlimab en 25 op placebo. De placebo patiënten kunnen naar de ernstig zieke patiënten studie als dat nodig is. De dokter die de eerste 10 patiënten heeft geïnjecteerd denkt dat de studie snel zal vollopen. Om logistieke redenen zal de studie in maximaal 10 ziekenhuizen lopen waarbij de coördinatie wordt gedaan door het NY ziekenhuis waar de eerste patiënten zijn gedoseerd. Duur van de studie: twee weken plus drie weken.

    Ziekenhuizen in de UK en Italië zitten te wachten op het groene licht van de FDA. Zodra dat verstrekt is worden er ook patiënten in de UK en Italië behandeld.

    fc
1.071 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 54 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 866,73 +0,16%
EUR/USD 1,0676 +0,04%
FTSE 100 7.865,80 +0,23%
Germany40^ 17.783,40 +0,08%
Gold spot 2.383,27 +0,94%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

VIVORY...
+11,51%
Alfen ...
+4,12%
Air Fr...
+3,80%
JUST E...
+3,60%
B&S Gr...
+2,42%

Dalers

Pharming
-8,28%
PostNL
-5,46%
ASMI
-2,31%
Accsys
-1,94%
Avantium
-1,74%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!